Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy

AIDS

Volumn 17, Issue 10, 2003, Pages 1539-1545

  Dore, Gregory J ^a,b   McDonald, Ann ^a   Li, Yueming ^a   Kaldor, John M ^a   Brew, Bruce J ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

AIDS dementia complex; Antiretroviral therapy; HIV

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; FEMALE; FUNGAL MENINGITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SURVIVAL; SURVIVAL TIME; TOXOPLASMOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUSTRALIA; CD4 LYMPHOCYTE COUNT; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE;

EID: 0042869762     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200307040-00015     Document Type: Article

References (44)

1. Delta Coordinating Committee. Delta. A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
2. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
3. CEASAR Coordinating Committee. Randomised trail of addition of lamivudine or lamivudine plus loviride-zidovudine-containing regimens for patients with HIV-1 infection: the CEASAR trail. Lancet 1997, 349:1413-1421.
4. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM Currier JS, et al. A controlled trail of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
5. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997, 11:1731-1738.
6. Mouton Y, Alfandari S, Valette M, Carier F, Dellamonica P, Humbert G, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997, 11:F101-F105.
7. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
8. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279:450-454.
9. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997, 315:1194-1199.
10. Correll PK, Law MG, McDonald AM, Cooper DA, Kaldor JM. HIV disease progression in the time of combination antiretroviral therapies. Med J Aust 1998, 169:468-472.
11. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999, 13:1933-1942.
12. Holtzer CD, Jacobsen MA, Hadley WK, Huang L, Stanley HD, Montanti R, et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994-1997. AIDS 1998, 12:1931-1933.
13. Centers for Disease Control and Prevention. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR 1999, 48(SS-2):1-22.
14. Mocroft A, Sabin CA, Youle M, Madge S, Devereux H, Deayton J, et al. Changes in AIDS defining illnesses, Royal Free Hospital 1987-1998. J Acquir Immune Defic Syndr 1999, 21, 401-407.
15. Abgrall S, Rabaud C, Costagliola D and the Clinical Epidemiology Group of the French Hospital Database on HIV. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis 2001, 33:1747-1755.
16. Derouin F, Gangneux J-P. Changing patterns of disease and treatment of opportunistic parasitic infections in patients with AIDS. Curr Opin Infect Dis 1998, 11:711-716.
17. McNaghten AD, Hanson DL, Jones JL and the Adult/Adolescent Spectrum of Disease Group. Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. AIDS 1999, 13:1687-1695.
18. Pezzotti P, Napoli PA, Acciai S, Boros S, Urciuoli R, Lazzeri V, et al. Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. AIDS 1999, 13:249-255.
19. Porta D, Rapiti E, Forastiere F for the Lazio AIDS Surveillance Collaborative Group. Changes in survival among people with AIDS in Lazio, Italy from 1993 to 1998. AIDS 1999, 13:2125-2131.
20. Li Y, Mcdonald AM, Dore GJ, for the National HIV Surveillance Committee. Improving survival following AIDS in Australia, 1991-1996. AIDS 2000, 14:2349-2354.
21. Conti S, Masocco M, Pezzotti P, Toccaceli V, Vichi M, Boros S, et al. Differential impact of combined antiretroviral therapy on the survival of Italian patients with specific AIDS-defining illnesses. J Acquir Immune Defic Syndrom Human Retrovirol 2000, 25:451-458.
22. Dore GJ, Li Y, McDonald A for the National HIV Surveillance Committee. Impact of highly active antiretroviral therapy on individual AIDS-defining illness incidence and survival in Australia. J AIDS 2002, 29:388-395.
23. Dote GJ, Correll P, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999, 13:1249-1253.
24. Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, et al. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS 1999, 13:1677-1685.
25. Stankoff B, Tourbah A, Suarez S, Turell E, Stievenart JL, Payan C, et al. Clinical and spectroscopic improvement in HIV-associated cognitive impairment. Neurology 2001, 56:112-115.
26. Kaldor J, McDonald AM, Blumer CE, Gertig DM, Patten JJ, Roberts M, et al. The acquired immunodeficiency syndrome in Australia: incidence 1982-1991. Med J Aust 1993, 158:10-17.
27. Australian National Council on AIDS. Definition of HIV infection and AIDS-defining illness. ANCA Bull 1994, 18:1.
28. Centers for Disease Control and Prevention. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987, 36(Suppl. 1S):3S-15S.
29. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17):1-19.
30. American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus type 1 (HIV-1) infection. Neurol 1991, 41:778-785.
31. National Centre in HIV Epidemiology and Clinical Research. Australian HIV Observational Database: Biannual Treatments Report, Vol. 1, No. 1. Canberra: National Centre in HIV Epidemiology and Clinical Research; November 1999:1-3.
32. Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985, 4:87-90.
33. Dore GJ, Hoy JF, Mallal SA, Mijch AM, French MA, Cooper DA, et al. Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:9-43.
34. Gail MH, Tan WY, Pee D, Goedert JJ. Survival after AIDS diagnosis in a cohort of hemophilia patients. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15:363-369.
35. Dougherty RH, Skolasky RL Jr, McArthur JC. Progression of HIV-associated dementia treated with HAART. AIDS Reader 2002, 12:69-74.
36. Deutsch R, Ellis RJ, McCutchan JA, Marcotte TD, Letendre S, Grant I for the HNRC Group. AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. AIDS 2001, 15:1898-1899.
37. Hutchinson SJ, Brettle RP, Gore SM. Predicting survival in AIDS: refining the model. Q J Med 1997, 90:685-692.
38. Chaisson RE, Gallant JE, Keruly JC, Moore RD. Impact of opportunistic disease on survival in patients with HIV infection. AIDS 1998, 12:29-33.
39. Bouwman FH, Skolasky RL, Hes D, Selnes OA, Glass JD, Nance-Sproson TE, et al. Variable progression of HIV-associated dementia. Neurology 1998, 50:1814-1820.
40. Wilkie FL, Goodwin K, Eisdorfer C, Feaster D, Morgan R, Fletcher MA, et al. Mild cognitive impairment and risk of mortality in HIV-1 infection. J Neuropsychiatr Clin Neurosci 1998, 10:125-132.
41. de Luca A, Giancola ML, Ammassari A, Grisetti S, Paglia MG, Gentile M, et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 2000, 182:1077-1083.
42. Dworkin MS, Wan PC, Hanson DL, Jones JL. Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis 1999, 180:621-625.
43. Flexner C. HIV-protease inhibitors. N Engl J Med 1998, 338:1281-1292.
44. Foudraine NA, Hoetelmans RMW, Lange JMA, de Wolf F, van Benthern BH, Maas JJ, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998, 351:1547-1551.